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http://www.biomedcentral.com/1471-2377/13/210RESEARCH ARTICLE Open AccessThe role of IFITM3 in the growth and migration of
human glioma cells
Bing Zhao*, Hongliang Wang, Gang Zong and Ping LiAbstract
Background: Interferon induced transmembrane protein 3 (IFITM3) is transcribed in most tissues and highly
interferon-inducible. However, the role of IFITM3 in cancer is still poorly understood.
Methods: Expression levels ofIFITM3were analyzed in 60 glioma patients by immunohistochemistry (IHC). Following
closely, we investigated the phenotype of IFITM3 knockdown on glioma cell growth and tumorigenesis in vitro
using lentivirus-mediated loss-of-function strategy.
Results: Depletion of IFITM3in U251 cells dramatically inhibited cell proliferation and colony formation, which
demonstrated that reduced IFITM3 protein levels could cause inhibition of tumorigenesis. Knockdown of IFITM3 also
induced cell cycle arrest in G0/G1 phase, especially in the sub-G1 phase representing apoptotic cells. In addition,
the migration of U251 cells was visibly weakened after IFITM3 knockdown, as determined by Transwell assay.
Conclusions: Our findings provide new evidence that IFITM3 plays an important role in glioma cell growth and
migration, suggesting that silencing of IFITM3 by RNA interference (RNAi) may be a potential approach to suppress
glioma growth.
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Glioma is the most common neurosurgical Nerve tumor
[1,2]. At present, the prognosis of patients with malig-
nant glioma remains very poor, and median survival is
generally less than one year from the time of diagnosis,
even in the most favorable situations, most patients die
within two years [3,4]. Numerous studies have shown
that gliomas develop as a result of genetic alterations
that accumulate with tumor progression and therefore
show a great morphological and genetic heterogeneity.
Primary and secondary glioblastomas represent distinct
entities evolving through different genetic pathways, mo-
lecular profile and response to therapy [5]. Therefore,
new molecular targets and therapeutic strategies are ur-
gently required for glioma therapy.
Interferon induced transmembrane protein 3 (IFITM3,
also known as 1-8U) was initially identified in a cDNA
screen from INF-treated neuroblastoma cell back in
1984 [6] and cloned from a human lymphoid cell cDNA* Correspondence: bingzhaodr@163.com
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reproduction in any medium, provided the orlibrary [7]. IFITM3 is transcribed in most tissues and is
highly interferon-inducible [7,8]. Previous studies showed
that IFITM3 belongs to a family of murine genes [9], which
are short, 2-transmembrane-domain proteins (5-18 kDa)
with high core sequence similarity but divergent N- and
C-termini. The human homologues (IFITM1, IFITM2,
and IFITM3) are clustered on chromosome 11 within
an 18-kb genomic sequence [7,10,11], and mediates cel-
lular processes, including cell adhesion, immune-cell
regulation, germ-cell homing and maturation, and bone
mineralization [8,11-16].
Recent studies identified possible roles of IFITM genes
in carcinogenesis. For example, IFITM1 and IFITM3
were shown to express at higher levels in astrocytoma
cells than in normal astrocytes in mice [11,17,18]. Fur-
thermore, IFITM1 was identified as a key player in both
the carcinogenesis and invasion in patients with glioma
[19]. Also, IFITM2 played a crucial role as a p53 inde-
pendent pro-apoptotic gene in regulating cancer cellular
pathways to death [20]. Researchers first isolated the
IFITM3 gene from tumor tissue and severely inflamed
mucosa in the colons of patients with ulcerative colitis,td. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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associated colon cancer [21,22]. In addition, IFITM3
expression has been found to be up-regulated in gastric
cancer, colorectal tumors, and so on [23-25].
In this study, we showed the positive correlation be-
tween the expression levels of IFITM3 and pathological
grades of glioma by IHC. However, the precise function
and underlying mechanism of IFITM3 in glioma patho-
genesis remain unclear. To study the role of IFITM3 in
glioma, we employed lentivirus-mediated short hairpin
RNA (shRNA) to knock down IFITM3 in human glioma
cell line U251. The effects of IFITM3 knockdown on cell
growth and migration were investigated.
Methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM) and fetal
bovine serum (FBS) were obtained from Hyclone (Logan,
Utah, USA). Lipofectamine 2000, TRIzol® Reagent was
purchased from Invitrogen (Carlsbad, CA, USA). M-MLV
Reverse Transcriptase was purchased from Promega
(Madison, WI, USA; cat. M1705). All other chemicals were
obtained from Sigma (St. Louis, MO, USA). The antibodies
used were as follows: anti-IFITM3 (1:50 dilution; Sigma/
SAB1410086).
Immunohistochemistry (IHC)
We studied 60 glioma patients who had been surgically
treated in Department of Neurosurgery, the Second
Affiliated Hospital of Anhui Medical University, Hefei
230601, China. For IHC, 60 pairs of resected glioma tis-
sues were fixed in 10% formalin solution and embedded
in paraffin. Histological slices of 3 mm were prepared,
then were deparaffined in xylene, and rehydrated with
graded ethanol. Endogenous peroxidase was blocked with
0.3% H2O2 in methanol for 20 min at room temperature
(RT). Following antigen retrieval, the sections were blocked
with 5% BSA for 20 min at RT and then probed with 1:300
rabbit anti-IFITM3 at 4°C overnight. After washing, the
sections were incubated with Histostain○R-Plus 3rd Gen
IHC Detection Kit (Invitrogen/85–9073) at RT for 1 h,
and visualized using the peroxidase conjugated streptavi-
din and diaminobenzidine, followed by counterstaining
with Mayer’s haematoxylin. The IFITM3 antibody was
replaced by PBS in negative controls. IHC staining were
evaluated by a pathologist blinded to all clinical data.
Samples were scored positive when more than 10% of
the cells reacted with the anti-IFITM3 antibody and pre-
sented cytoplasm staining.
Cell culture
Human glioma cell line U251 and human embryonic
kidney cell line 293 T were obtained from American
Type Culture Collection (ATCC). Cells were maintainedin DMEM supplemented with 10% heat-inactivated FBS
and 100 units/ml penicillin/streptomycin at 37°C in hu-
midified atmosphere of 5% CO2.
Construction of IFITM3 shRNA lentivirus vector and
cell infection
The following oligonucleotide was synthesized. The
negative control small interfering RNA (siRNA) was 5′-
TTCTCCGAACGTGTCACGT-3′. IFITM3 siRNA was
5′-GCTGGAATTCATGAATCACACTGTCCAAAC-3′.
The stem-loop-stem oligos (shRNAs) were synthesized,
annealed, and ligated into the Nhe I/Pac I-linearized
pFH-L vector. The lentiviral-based shRNA-expressing vec-
tors were confirmed by DNA sequencing. The generated
plasmids were named as pFH-L-shIFITM3 or -shCon. Re-
combinant lentiviral vectors and packaging vectors were
then transfected into 293 T cells. Supernatants containing
lentivirus expressing IFITM3 shRNA or control shRNA
were harvested 72 h after transfection. Then, the lentivi-
ruses were purified using ultracentrifugation, and the titer
of lentiviruses was determined. U251 cells were infected
with the lentivirus constructs at multiplicity of infection
(MOI) =10 and mock-infected cells were used as negative
controls. To demonstrate specific knockdown of IFITM3,




AGAATGGTCATGAGGTTTTT-3′) against IFITM3 to
get comparable results.
RT-PCR
Total RNA was extracted from U251 cells 5 days after
infection using TRIzol® Reagent. cDNA was synthesized
using M-MLV Reverse Transcriptase. In brief, a mixture
containing 1.5 μg of total RNA, 0.75 μg oligo-dT primer
(Shanghai Sangon) and nuclease-free water in a total
volume of 13.5 μl was heated at 70°C for 5 min and then
cooled on ice for another 5 min. The mixture was sup-
plemented with 4 μl M-MLV buffer, 1.25 μl dNTP, 0.5 μl
RNasin and 0.75 μl M-MLV-RT up to a final volume of
20 μl, followed by incubation at 42°C for 60 min.
Real-time quantitative PCR
Real-time quantitative PCR analysis was performed
using SYBR Green Master Mix Kit on BioRad connect
Real-Time PCR platform. In brief, each PCR reaction
mixture containing 10 μl of 2 × SYBR GreenMaster Mix,
1 μl of sense and antisense primers (5 μmol/μl) and 1 μl
of cDNA (10 ng), was run for 45 cycles with denatur-
ation at 95°C for 15 s, annealing at 60°C for 30 s and ex-
tension at 72°C for 30 s in a total volume of 20 μl. For
relative quantification, 2-ΔΔCT was calculated and used
as an indication of the relative expression levels, which
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from the CT values of IFITM3. The primer sequences for
PCR amplification of IFITM3 gene were 5′-TGTCCA
AACCTTCTTCTCTCC-3′ and 5′-CGTCGCCAACCAT
CTTCC-3′. β-actin was applied as an internal control.




U251 cells were trypsinized, resuspended, seeded into
96-well plate with a concentration of 2000 cells per well,
and incubated at 37°C 3 days post lentivirus infection.
The number of viable cells was measured at daily inter-
vals (day 1, 2, 3, 4 and 5). At each time point, 10 μl of
5 mg/ml MTT (Dingguo Biotechnology) was added, and
incubation was continued for 3 h. Then the medium
was removed carefully and 100 μl of acidified isopro-
panol (in 0.01 M HCl) was added at the end of incu-
bation. The absorbance was measured at 595 nm on the
spectrophotometer.
Colony formation assay
A total of 200 U251 cells were seeded in 6-well plates
after 3 days of lentivirus infection. The medium was
changed at regular time intervals. After 11 days of cul-
tureat 37°C, the natural colonies were washed with PBS
and fixed with 4% paraformaldehyde for 30 min at room
temperature. The colonies were then stained with Giemsa
for 10 min, washed with water and air-dried. The totalFigure 1 Representative immunohistochemical staining for IFITM3 in
(WHO I); B astrocytoma (WHO II); C anaplastic astrocytoma (WHO III); D munumber of colonies with more than 50 cells was counted
under fluorescence microscopy.
Fluorescence-activated cell sorting analysis
The cell cycle distribution was analyzed using flow cy-
tometry with PI staining. In brief, 1.5 × 105 cells that
infected with lentivirus for 4 days were seeded in 6-cm
dishes and allowed to culture for 40 h at 37°C. Cells
were harvested after tripsinization, washed with PBS,
and fixed with 70% cold ethanol. Cells were then col-
lected by centrifugation, resuspended in PBS containing
100 μg/ml of DNase-free RNase and 40 μg/ml PI, and
incubated for 1 h at 37°C. A total of 1.0 × 104 fixed cells
were analyzed by FACS can (Becton-Dickinson, Franklin
Lakes, NJ, USA).
Cell migration assay
U251 cells were infected with Lv-shIFITM3 for 4 days,
and the in vitro migration ability was determined using a
Transwell chamber (Corning, NY, USA). Briefly, cells
were seeded into the upper chamber of the transwell
plates (8.0 μm pore, Corning Costar, Cambridge, MA)
with 3.0 × 104 cells/well in 200 μl of serum-free medium,
and 500 μl medium containing 10% FBS was added to
the lower chamber as a chemoattractant. After incuba-
tion for 24 h at 37°C in 5% CO2, the cells remaining on
the upper surface of the filter were removed, and those
that invaded to the lower compartment were fixed
with Methanol and stained with crystal violet. Cells
were counted visually in 5 random fields under lightpatients with different grade glioma. A pilocytic astrocytoma
ltiple glioblastoma (WHO IV). Original magnification 200 ×.
Table 1 The relationship between the incidence of
immunoreactivity for IFITM3 in human glioma tissue











32 2 (6.3%) 30 (93.8%)
N: number of samples.
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were dissociated, lysed and quantified at 570 nm using
spectrophotometer.
Statistical analysis
All data were expressed as mean ± SD of three independ-
ent experiments, in which each assay was performed in
triplicate. The results were analyzed statistically using
the chi-square test for the relationship between the inci-
dence of immunoreactivity for IFITM3 and the histo-
logical grades using GrafPad Prism version 5.0. TheFigure 2 Lentivirus-mediated gene silencing of IFITM3 in glioma cells. (A
and U373 glioma cells; (B) Determination of infection efficiency in the human
infection were shown (10× objective lens). (C) Expression analysis of IFITM3
Lv-shCon, and cells infected with Lv-shIFITM3. The β-actin gene is the internal
(D) Expression analysis of IFITM3 protein in uninfected group, Lv-shCon groupStudent’s t-test was used to evaluate the differences be-
tween the control cells and IFITM3 knockdown cells
using SPSS 13.0 software. P < 0.05 was considered as
statistically significant.
Results and discussion
Overexpression of IFITM3 in human glioma tissues
To evaluate the role of IFITM3in human glioma, IHC
was performed to analyze the expression levels of IFITM3
in 60 glioma patients (grade I:7; grade II:25; grade III:17;
grade IV:11). According to the World Health Organization
(WHO) classification, low-grade gliomas encompass grade
I and grade II tumors with the least malignant phenotypes,
while high-grade gliomas encompass grade III (anaplastic
astrocytoma, anaplastic oligoastrocytoma, and anaplastic
oligodendroglioma) and grade IV (glioblastoma [GBM])
tumor with the most malignant phenotype [26]. Com-
pared with the low grade glioma groups (Figure 1A
and B), IFITM3 positive staining was mostly observed in
high grade glioma (Figure 1C and D). IFITM3 expression
level was increased with the histological grade of glioma
(Table 1, P < 0.05). We also provided positive control and) Quantitative RT-PCR analysis for IFITM3 mRNA levels in U251, U87-MG
glioma cells. Representive images of U251 cells after 3 days of lentivirus
mRNA by qRT-PCR in uninfected U251 cell (Con), cells infected with
controls for qRT-PCR. Significant difference from Lv-shCon (P < 0.001).
and Lv-shIFITM3 group by western blot.
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antibody was replaced by PBS, as shown in Additional
file 1: Figure S1. These data clearly indicate that
IFITM3 is specifically overexpressed in glioma tissues,
and its high expression may contribute to the patho-
genesis of glioma.
Knockdown of IFITM3 in U251 cells by lentivirus infection
Human glioma cells of different transformation degrees,
as represented by U373 astrocytoma (WHO grade III),
U87-MG and U251 glioblastoma multiforme (WHO
grade IV) were selected to detect IFITM3 expression. As
shown in Figure 2A, high expression levels of IFITM3
were observed in all three cells. U251 cells, derived from
a high-grade glioblastoma, were used for the following
loss-of-function investigation. We constructed a lenti-
viral vector system to express siRNA targeting IFITM3
and to express GFP as a reporter gene. To determine the
efficacy of recombinant lentiviruses, U251 cells infected
with Lv-shIFITM3 and Lv-shCon were observed under aFigure 3 Lv-shIFITM3 infection inhibits the proliferation and colony fo
without infection (Con), cells infected with Lv-shCon, and cells infected with
inhibited, as demonstrated by MTT assay. Significant difference from Lv-shCon
microscope, representing the size and number of colonies in each group of ce
Significant difference from Lv-shCon (P< 0.01).fluorescence microscope. More than 90% of the cells
expressed GFP after 72 h infection (Figure 2B), which
indicated high-efficiency infection by Lv-shIFITM3. To
verify that the IFITM3 gene was silenced by Lv-shIFITM3,
we determined the mRNA levels in uninfected, Lv-shCon
and Lv-shIFITM3-infected cells by qRT-PCR. Cell infected
with Lv-shIFITM3 exhibited significant decreased IFITM3
mRNA levels, by 84.8% reduction in U251 cells, compared
with Lv-shCon-infected and uninfected cells (Figure 2C,
P < 0.001). The similar result was observed in U251 cells
infected with another two shRNA stargeting IFITM3,
respectively (Additional file 2: Figure S2 A, P < 0.001).
To confirm the silencing of IFITM3, western blot was
used using IFITM3 antibodies. Compared with unin-
fected and Lv-shCon infected cells, the IFITM3 protein
level was significantly decreased in U251 cells infected
with the Lv-shIFITM3 (Figure 2D). Similarly, only weak
band was detected in U251 cells infected with another
two shRNAs targeting IFITM3, respectively, while the
high expression of IFITM3 was not affected in cellsrmation of U251 cells. (A) In vitro proliferation assay of U251 cells
Lv-shIFITM3. Cell proliferation in the Lv-shIFITM3 group was significantly
(P < 0.001). (B) Images recorded under light microscope and fluorescence
lls. (C) Statistical analysis of the number of colonies with Giemsa staining.
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(Additional file 2: Figure S2 B).
Knockdown of IFITM3 inhibited cell proliferation
MTT assay was performed to investigate the effect of
IFITM3 knockdown on cell proliferation. The growth
curve obtained from the MTT assay indicated that the
proliferative ability of Lv-shIFITM3-infected cells was
significantly decreased, by 55.2% reduction in U251 cells,
when compared with that of Lv-shCon-infected cells
(P < 0.001, Figure 3A). The similar results could be seen in
Additional file 2: Figure S2 C, the proliferative ability of
Lv-shIFITM3-S2-infected and Lv-shIFITM3-S3-infected
cells was significantly decreased, respectively. These results
indicate that knockdown of IFITM3 by RNAi could inhibit
the proliferation of glioma cells.
Downregulation of IFITM3 suppressed colony formation
To determine whether IFITM3 has any impact on the
colony-forming capacity of glioma cells, colony forma-
tion assay was performed. Our data indicated that theFigure 4 Knockdown of IFITM3 blocks cell cycle progression in U251
cytometry. (B) Compared with Lv-shCon, the population of cells in the G0/G
(C) Percentage of apoptotic cells showed a significant increase in the Lv-shInumber and size of colonies formed fromLv-shIFITM3-
infected cells were strongly decreased, by 78.8% reduc-
tion in U251 cells, compared with Lv-shCon-infected
cells (Figure 3B and C, P < 0.01), suggesting that the re-
duced expression of IFITM3 could significantly inhibit
colony formation in glioma cells.
Depletion of IFITM3 induced cell cycle arrest as well
as apoptosis
To elucidate whether knockdown of IFITM3 inhibits cell
growth by affecting cell cycle progression, we assessed
the cell cycle distribution in U251 cells by flow cytometry
(Figure 4A). As shown in Figure 4B, compared to control
groups, cell population in the Lv-shIFITM3 group
displayed a significant decrease in S phase (Lv-shCon
56.58% ± 0.36% vs 60.07% ± 0.90%, P < 0.01), and a signifi-
cant increase in G0/G1 phase (Lv-shCon 56.58% ± 0.36%
vs 60.07% ± 0.90%, P < 0.05). Accumulation of cells in the
sub-G1 fraction was clearly observed in the Lv-shIFITM3
group compared to Lv-shCon group (Lv-shCon 1.09% ±
0.07%vs 3.35% ± 0.32%, P < 0.01) (Figure 4C). Takencells. (A) Cell cycle distribution of U251 cells was analyzed by flow
1 and S phase were increased the Lv-shIFITM3 group (P < 0.05, P < 0.01).
FITM3 group. Significant difference from Lv-shCon (P < 0.01).
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cell growth via cell cycle regulation as well as apoptosis.
Downregulation of IFITM3 attenuated cell migration
To detect whether knockdown of IFITM3 affects the mi-
gration of glioma cells, Transwell migration assay was
performed to assess the proportion of U251 cells which
migrated through polycarbonate membranes following
4 days of lentivirus infection. We found that IFITM3
knockdown reduced the number of invaded cells account-
ing for 65.5% reduction in U251 cells (Figure 5A and B,
P < 0.01). In addition, the colorimetric assay showed
that the motility capability of U251 cells were retained
after Lv-shIFITM3 infection (P < 0.01, Figure 5C).
Conclusions
Glioma is triggered by a series of point mutations and
genetic alterations that progressively cause normal cells
to transform into precancerous cell which could become
more dysplastic, resulting in carcinoma foci [27]. At
present, the identification of useful markers for the diag-
nosis of human glioma is a major goal in cancer re-
search, which also provides valuable information in tumorFigure 5 Lv-shIFITM3 infection induces reduction in migration capacit
representing that IFITM3 knockdown could reduce the motility of U251 cel
after Lv-shIFITM3 infection for 4 days. Significant difference from Lv-shConpathogenesis. We analyzed the expression of IFITM3 in
human glioma specimens by immunohistochemistry and
found the expression levels of IFITM3 were up-regulated
in varying degrees and positively correlated with glioma of
pathological grade I ~ II and III ~ IV (P < 0.05). Meanwhile,
recent studies have also shown that IFITM3 plays a prom-
inent role in tumor development and can be used as a
tumor biomarker [21-25]. However, the precise role of
IFITM3 in glioma pathogenesis remains unknown.
In recent few years the discovery of RNAi, a powerful
tool to induce loss-of-function phenotypes through the
posttranscriptional silencing of gene expression, has pro-
vided new possibilities for cancer therapy [28-30]. In our
study, lentivirus-mediated RNAi was used to knock
down IFITM3 in human glioma cells. The siRNA target-
ing IFITM3, which expressed from the recombinant
lentivirus, induced efficient and specific inhibition of en-
dogenous IFITM3 mRNA in U251 cells. Simultaneously,
depletion of IFITM3 led to significant reduced cell prolif-
eration, colony formation and cell migration in U251
cells. Thus, this study confirms a crucial role of IFITM3 in
glioma tumorigenesis, suggesting IFITM3 as an oncogene
in human glioma.y of U251 cell. (A) Images recorded under light microscope,
ls. (B and C) Statistical analysis of OD570 and cell count in U251 cells
(P < 0.01).
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of IFITM3 remarkably induced U251 cells accumulation in
G0/G1 phase, especially in sub-G1 phase, which represents
cell apoptosis [31]. Together, IFITM3 may promote human
glioma growth by inducing cell cycle arrest and apoptosis.
Based on the IFITM3 belong to 2-transmembrane-domain
proteins (5-18 kDa) with high core sequence similarity
but divergent N- and C-termini, we suggest IFITM3 as a
growth regulator in glioma, and it may be involved in the
control of transport essential raw materials for DNA and
enzymic synthesis process in cell cycle progression.
However, some studies indicated IFITM3 plays an im-
portant role in inhibiting tumor development. For in-
stance, El-Tanani et al. [32] found that IFITM3 in breast
cancer physically interacts with OPN and reduces OPN
mRNA expression, which mediates cancer cell adhesion,
cell invasion and colony formation. Similar situation has
come under observation in human melanoma, and it is
deemed dynamic promoter methylation adds an add-
itional layer of complexity to the IFN-α key response
genes like IFITM3 be required for comprehensive con-
trol of the IFN-α response [33,34]. Therefore, we think
the roles of IFITM3 in various cancers possibly depend on
tumor growth microenvironment. Under normal physio-
logical circumstances, IFITM3 could be in a balance regu-
lating by different signal pathways.
Furthermore, local invasion is one of the primary rea-
sons for clinical treatment failure in malignant gliomas.
Recently, there has been increasing evidence regarding
specific molecules that determine the aggressiveness and
invasion potential of high grade astrocytic tumors [35].
In our study, we found IFITM3 knockdown significantly
reduced the migration capacity of U251 cells, indicating
that IFITM3 might play an essential role in glioma me-
tastasis. However, further experiments are needed to elu-
cidate the mechanism of IFITM3 in glioma cell growth
and migration.
To sum up, knockdown of IFITM3 by RNAi successfully
reduced cell proliferation and migration, and promoted
apoptosis in glioma cells. Our results provide new evidence
for the involvement of IFITM3 in carcinogenesis, and sug-
gest that RNAi-directed IFITM3 silencing may be a potent
therapeutic tool in glioma.
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